[8-K] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Reports Material Event
Cyclacel Pharmaceuticals disclosed that it is presenting audited consolidated financial statements for the quarter ended March 31, 2025 to satisfy the eligibility requirements of a registration statement on Form S-3. The filing indicates the company is providing its audited quarter-end financials and related notes so it meets the stated Form S-3 condition for shelf or registered offerings.
The report lists two exhibits: Exhibit 99.1 (the audited financial statements for the quarter) and Exhibit 104 (the cover page interactive XBRL data). The filing itself does not include income statement, balance sheet, or management discussion figures within the report text provided.
Cyclacel Pharmaceuticals ha comunicato di presentare i bilanci consolidati sottoposti a revisione contabile per il trimestre chiuso il 31 marzo 2025, per soddisfare i requisiti di ammissibilità di una dichiarazione di registrazione sul Form S-3. La comunicazione indica che la società fornisce i suoi bilanci trimestrali revisionati e le relative note in modo da ottemperare alla condizione prevista dal Form S-3 per offerte in regime di shelf o offerte registrate.
Il rapporto elenca due allegati: Exhibit 99.1 (i bilanci trimestrali revisionati) e Exhibit 104 (la pagina di copertina in formato XBRL interattivo). La stessa presentazione non include nel testo fornito le cifre del conto economico, dello stato patrimoniale o la discussione della direzione.
Cyclacel Pharmaceuticals informó que está presentando los estados financieros consolidados auditados correspondientes al trimestre terminado el 31 de marzo de 2025 para cumplir los requisitos de elegibilidad de una declaración de registro en el Form S-3. La presentación indica que la compañía está proporcionando sus estados financieros trimestrales auditados y las notas relacionadas para cumplir la condición establecida por el Form S-3 para ofertas en shelf o registradas.
El informe enumera dos anexos: Exhibit 99.1 (los estados financieros auditados del trimestre) y Exhibit 104 (la página de portada en datos XBRL interactivos). La propia presentación no incluye, en el texto facilitado, cifras del estado de resultados, del balance ni la discusión de la dirección.
Cyclacel Pharmaceuticals는 등록명세서 Form S-3의 자격요건을 충족하기 위해 2025년 3월 31일로 종료된 분기에 대한 감사된 연결 재무제표를 제출하고 있다고 공시했습니다. 이 제출자료는 회사가 Form S-3의 해당 조건을 충족하기 위해 분기말 감사 재무제표 및 관련 주석을 제공하고 있음을 밝힙니다.
보고서에는 두 개의 증빙문서가 기재되어 있습니다: Exhibit 99.1 (해당 분기의 감사 재무제표) 및 Exhibit 104 (표지 페이지의 인터랙티브 XBRL 데이터). 제출본에는 제공된 본문 내에 손익계산서, 대차대조표 또는 경영진의 논의 수치가 포함되어 있지 않습니다.
Cyclacel Pharmaceuticals a indiqué qu'elle présente les états financiers consolidés audités pour le trimestre clos le 31 mars 2025 afin de satisfaire aux critères d'éligibilité d'une déclaration d'enregistrement sur le Form S-3. Le dépôt précise que la société fournit ses états financiers trimestriels audités et les notes associées pour répondre à la condition énoncée par le Form S-3 en vue d'offres sur shelf ou d'offres enregistrées.
Le rapport énumère deux annexes : Exhibit 99.1 (les états financiers audités du trimestre) et Exhibit 104 (la page de couverture en données XBRL interactives). Le dépôt lui‑même n'inclut pas, dans le texte fourni, les chiffres du compte de résultat, du bilan ni les commentaires de la direction.
Cyclacel Pharmaceuticals gab bekannt, dass es für das auf den 31. März 2025 endende Quartal geprüfte konsolidierte Abschlüsse vorlegt, um die Zulassungsvoraussetzungen einer Registrierungserklärung auf Form S-3 zu erfüllen. Die Einreichung weist darauf hin, dass das Unternehmen seine geprüften Quartalsabschlüsse und die dazugehörigen Anmerkungen bereitstellt, um die im Form S-3 geforderte Bedingung für Shelf- oder registrierte Angebote zu erfüllen.
Der Bericht nennt zwei Anlagen: Exhibit 99.1 (die geprüften Quartalsabschlüsse) und Exhibit 104 (die Titelseite als interaktive XBRL-Daten). Die Einreichung selbst enthält im bereitgestellten Text keine Angaben zu Gewinn- und Verlustrechnung, Bilanz oder zur Management-Diskussion.
- None.
- None.
Insights
TL;DR: Routine procedural filing supplying audited Q1 2025 statements to maintain Form S-3 eligibility; no operating metrics disclosed here.
The submission is primarily administrative: Cyclacel is furnishing audited consolidated financials for the quarter ended March 31, 2025 and including XBRL cover page data. That action addresses a technical requirement under Form S-3 instructions and preserves the company’s ability to rely on that registration form for future offerings. Because the filing contains no revenue, profit, cash balance, or reserve figures in the disclosed text, there is no immediate financial information to revalue the business or change forecasts. Impact on investors is therefore neutral absent the underlying exhibits.
TL;DR: Compliance-focused disclosure; providing audited quarter-end statements and XBRL data is standard governance practice to satisfy S-3 criteria.
Delivering audited consolidated financial statements and an interactive data cover page reflects adherence to disclosure and filing standards tied to Form S-3 eligibility. This supports regulatory compliance and investor transparency from a procedural perspective. The filing text does not include management commentary or specific financial metrics, so governance implications are limited to confirming the company met the stated submission requirement. Overall governance impact is neutral.
Cyclacel Pharmaceuticals ha comunicato di presentare i bilanci consolidati sottoposti a revisione contabile per il trimestre chiuso il 31 marzo 2025, per soddisfare i requisiti di ammissibilità di una dichiarazione di registrazione sul Form S-3. La comunicazione indica che la società fornisce i suoi bilanci trimestrali revisionati e le relative note in modo da ottemperare alla condizione prevista dal Form S-3 per offerte in regime di shelf o offerte registrate.
Il rapporto elenca due allegati: Exhibit 99.1 (i bilanci trimestrali revisionati) e Exhibit 104 (la pagina di copertina in formato XBRL interattivo). La stessa presentazione non include nel testo fornito le cifre del conto economico, dello stato patrimoniale o la discussione della direzione.
Cyclacel Pharmaceuticals informó que está presentando los estados financieros consolidados auditados correspondientes al trimestre terminado el 31 de marzo de 2025 para cumplir los requisitos de elegibilidad de una declaración de registro en el Form S-3. La presentación indica que la compañía está proporcionando sus estados financieros trimestrales auditados y las notas relacionadas para cumplir la condición establecida por el Form S-3 para ofertas en shelf o registradas.
El informe enumera dos anexos: Exhibit 99.1 (los estados financieros auditados del trimestre) y Exhibit 104 (la página de portada en datos XBRL interactivos). La propia presentación no incluye, en el texto facilitado, cifras del estado de resultados, del balance ni la discusión de la dirección.
Cyclacel Pharmaceuticals는 등록명세서 Form S-3의 자격요건을 충족하기 위해 2025년 3월 31일로 종료된 분기에 대한 감사된 연결 재무제표를 제출하고 있다고 공시했습니다. 이 제출자료는 회사가 Form S-3의 해당 조건을 충족하기 위해 분기말 감사 재무제표 및 관련 주석을 제공하고 있음을 밝힙니다.
보고서에는 두 개의 증빙문서가 기재되어 있습니다: Exhibit 99.1 (해당 분기의 감사 재무제표) 및 Exhibit 104 (표지 페이지의 인터랙티브 XBRL 데이터). 제출본에는 제공된 본문 내에 손익계산서, 대차대조표 또는 경영진의 논의 수치가 포함되어 있지 않습니다.
Cyclacel Pharmaceuticals a indiqué qu'elle présente les états financiers consolidés audités pour le trimestre clos le 31 mars 2025 afin de satisfaire aux critères d'éligibilité d'une déclaration d'enregistrement sur le Form S-3. Le dépôt précise que la société fournit ses états financiers trimestriels audités et les notes associées pour répondre à la condition énoncée par le Form S-3 en vue d'offres sur shelf ou d'offres enregistrées.
Le rapport énumère deux annexes : Exhibit 99.1 (les états financiers audités du trimestre) et Exhibit 104 (la page de couverture en données XBRL interactives). Le dépôt lui‑même n'inclut pas, dans le texte fourni, les chiffres du compte de résultat, du bilan ni les commentaires de la direction.
Cyclacel Pharmaceuticals gab bekannt, dass es für das auf den 31. März 2025 endende Quartal geprüfte konsolidierte Abschlüsse vorlegt, um die Zulassungsvoraussetzungen einer Registrierungserklärung auf Form S-3 zu erfüllen. Die Einreichung weist darauf hin, dass das Unternehmen seine geprüften Quartalsabschlüsse und die dazugehörigen Anmerkungen bereitstellt, um die im Form S-3 geforderte Bedingung für Shelf- oder registrierte Angebote zu erfüllen.
Der Bericht nennt zwei Anlagen: Exhibit 99.1 (die geprüften Quartalsabschlüsse) und Exhibit 104 (die Titelseite als interaktive XBRL-Daten). Die Einreichung selbst enthält im bereitgestellten Text keine Angaben zu Gewinn- und Verlustrechnung, Bilanz oder zur Management-Diskussion.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices) (Zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The Capital Market | ||||
| The Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 9.01. Financial Statements and Exhibits.
In reference to meeting the eligibility requirements under General Instructions I.A.4 of the registration statement on Form S-3, Cyclacel Pharmaceuticals, Inc., a Delaware corporation is presenting its audited consolidated financial statements for the quarter ended March 31, 2025, including the notes to such financial statements.
(d) Exhibits.
| Exhibit No. | Exhibit | |
| 99.1 | Audited Financial Statements for the quarter ended March 31, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: August 12, 2025 | Cyclacel Pharmaceuticals, Inc. | |
| By: | /s/ Datuk Dr. Doris Wong Sing Ee | |
| Name: | Datuk Dr. Doris Wong Sing Ee | |
| Title: | Chief Executive Officer and Executive Director | |
| 3 |
